reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PNNT PENNANTPARK INVESTMENT
IPG INTERPUBLIC GROUP OF COMPANIES INC.
INTC INTEL CORPORATION
BLBD BLUE BIRD
ACGL ARCH CAPITAL GROUP LTD.
PRIM PRIMORIS SERVICES CORPORATION
UIHC UNITED INSURANCE HOLDINGS CORP.
LW LAMB WESTON HOLDINGS INC.
FLGT FULGENT GENETICS
KALV KALVISTA PHARMACEUTICALS
SYNH SYNEOS HEALTH INC. CLASS A
OFIX ORTHOFIX MEDICAL INC.
CMPR CIMPRESS PLC
IESC IES HOLDINGS INC.
ARRY ARRAY TECHNOLOGIES
LFST LIFESTANCE HEALTH GROUP INC
ASRT ASSERTIO HLDGS INC
CEGVV CONSTELLATION ENERGY CORPORATION
CR CRANE HOLDINGS CO
ISRG ISRAIR GROUP LTD
Moody's places Syneos Health's ratings on review for downgrade on LBO ...
Moody's Investors Service (Moody's) placed Syneos Health, Inc.'s ("Syneos") ratings on review for downgrade. This follows an announcement that Syneos will be acquired by an investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital. The ratings pla...
Moody's revises Syneos' outlook to negative; affirms CFR at Ba2
Moody's Investors Service (Moody's) revised Syneos Health, Inc.'s ("Syneos") outlook to negative from stable. At the same time, Moody's affirmed all other ratings including the Ba2 corporate family rating (CFR), the Ba2-PD probability of default rating (PDR), the Ba2 senior secured bank credit facil...
Moody's upgrades Syneos' CFR to Ba2; outlook stable
Moody's Investors Service ("Moody's") upgraded the ratings of Syneos Health, Inc. ("Syneos"), including the Corporate Family Rating to Ba2 from Ba3 and the Probability of Default Rating to Ba2-PD from Ba3-PD. Moody's also upgraded the senior unsecured ratings to B1 from B2. Concurrently, Moody's aff...
Syneos Health Inc: 3 directors
Three Directors at Syneos Health Inc sold 17,335 shares at between 72.810USD and 74.000USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
- Valens Research
Valens Equity Insights and Inflections - 2022 05 03
Akamai Technologies, Inc. (AKAM) has been rapidly growing its high-margin cybersecurity business. Uniform Accounting highlights the company's profitability potential as it grows these businesses, a trend the market seems to be missing, indicating equity upside is warranted. While Akamai's legacy CDN business is viewed by the market as a saturated utility, the company has been pivoting towards higher margin businesses like cybersecurity and Edge Computing, giving it the ability to reinvigorate ...
STOR STORE CAPITAL CORPORATION
NRG NRG ENERGY INC.
MU MICRON TECHNOLOGY INC.
BWA BORGWARNER INC.
BFAM BRIGHT HORIZONS FAMILY SOLUTIONS INC.
AKAM AKAMAI TECHNOLOGIES INC.
AEE AMEREN CORPORATION
SCI SERVICE CORPORATION INTERNATIONAL
LW LAMB WESTON HOLDINGS INC.
SYNH SYNEOS HEALTH INC. CLASS A
- Valens Research
SYNH - Embedded Expectations Analysis - 2022 05 02
Syneos Health, Inc. (SYNH) currently trades near corporate and historical averages relative to Uniform earnings, with a 19.1x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to fade to 40%, accompanied by 7% Uniform asset growth. However, analysts expect Uniform ROA to improve to 57% in 2023, accompanied by 3% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $103, representing approximately 33% equ...
SYNEOS HEALTH sees an upgrade to Slightly Positive due to a better fun...
The general evaluation of SYNEOS HEALTH (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 31, 2021, the closing price was U...
Moody's announces completion of a periodic review of ratings of Syneos...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Syneos Health, Inc.. Global Credit Research- 13 Dec 2021. New York, December 13, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Syneos Health, Inc. and other ratings that are associated with the same analytical unit.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.